Lv5
1130 积分 2022-03-23 加入
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors
10天前
已完结
肝胆肿瘤分子诊断临床应用专家共识
12天前
已完结
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline Clinical Insights
21天前
已关闭
The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base
1个月前
已完结
Pharmacological reactivation of p53 in the era of precision anticancer medicine
1个月前
已完结
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial
1个月前
已完结
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial
1个月前
已完结
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer
1个月前
已完结
微卫星不稳定性（MSI）检测技术专家共识
1个月前
已完结
Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both?
1个月前
已完结
皖公网安备34019202002308
